{"title":"AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1918","DOIUrl":null,"url":null,"abstract":"AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
